### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

N.T	C	
Name	OI	entity

Asian American Medical Group Limited

**ABN** 

42 091 559 125

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued **Ordinary Shares** 

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

19,000,000

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares as approved at the AGM held on 3 December 2015

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	A\$0.10
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	It is most likely that if the proposed acquisition of a 60% interest in Rich Tree Land Pte for a purchase price of \$19.6 million ( <b>Proposed Acquisition</b> ), which is currently subject to satisfaction of due diligence investigations, it will use the funds to partially fund the Proposed Acquisition. If the Proposed Acquisition does not proceed the net proceeds will be used for business diversification and expansion into new health-care related business services and general working capital purposes.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	Approved at the AGM held on 3 December 2015
6c	Number of *securities issued without security holder approval under rule 7.1	3,668,063
6d	Number of *securities issued with security holder approval under rule 7.1A	15,331,937

6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
6f	Number of *securities issued

Nil

under an exception in rule 7.2

d Nil

6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

Not Applicable

6h If \*securities were issued under 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not Applicable

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

LR 7.1: Nil LR 7.1A: 9,113,438

+Issue dates 7

> Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

26th January 2016 - 15,000,000 shares 27<sup>th</sup> January 2016 – 4,000,000 shares

8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
297,752,754	Fully paid Ordinary
	Shares

Appendix 3B Page 3 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

	Г	Number	+Class
0	Number and +class of all		Class
9	Number and *class of all *securities not quoted on ASX	Not Applicable	
	(including the *securities in		
	section 2 if applicable)		
	L		
10	Dividend policy (in the case of a	Not Applicable	
	trust, distribution policy) on the		
	increased capital (interests)		
Part 2	- Pro rata issue		
11		Not Applicable	
	required?		
12	Is the issue renounceable or non-	Not Applicable	
	renounceable?	11	
13	Ratio in which the *securities will be offered	Not Applicable	
	be offered		
14	<sup>+</sup> Class of <sup>+</sup> securities to which the	Not Applicable	
	offer relates		
	+D	NI . A 1' 11	
15	<sup>+</sup> Record date to determine entitlements	Not Applicable	
16	Will holdings on different	Not Applicable	
	registers (or subregisters) be		
	aggregated for calculating entitlements?		
17	Policy for deciding entitlements	Not Applicable	
	in relation to fractions		
18	Names of countries in which the	Not Applicable	
	entity has security holders who		
	will not be sent new offer documents		
	Note: Security holders must be told how their		
	entitlements are to be dealt with.		
	Cross reference: rule 7.7.		
10	Closing date for receipt of	Not Applicable	
19	acceptances or renunciations	Not Applicable	
	*		

20	Names of any underwriters	Not Applicable
21	Amount of any underwriting fee or commission	Not Applicable
22	Names of any brokers to the issue	Not Applicable
23	Fee or commission payable to the broker to the issue	Not Applicable
<b>2</b> 4	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not Applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not Applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not Applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not Applicable
28	Date rights trading will begin (if applicable)	Not Applicable
29	Date rights trading will end (if applicable)	Not Applicable
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not Applicable
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not Applicable

<sup>+</sup> See chapter 19 for defined terms.

32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not Applicable
33	<sup>+</sup> Issue date	Not Applicable
You need	3 - Quotation of securities d only complete this section if you are app	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	:1
(b)	•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
Entitie	s that have ticked box 34(a)	
Additi	onal securities forming a new	class of securities
Tick to docum	indicate you are providing the informatents	tion or
35	1 1	securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	1 1	y securities, a distribution schedule of the additional number of holders in the categories
	1,001 - 5,000 5,001 - 10,000	
	10,001 - 100,000 100,001 and over	
37	A copy of any trust deed for	the additional <sup>+</sup> securities

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 28 January 2016 Company secretary

Print name: DARIO NAZZARI

== == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	209,453,754 at 29 December 2014	
<ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	10,000,000 Placement Shares issued on 10 March 2015. 20,000,000 Placement Shares issued on 11 March 2015 5,000,000 Placement Shares issued on 29 December 2015	
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
Subtract the number of fully paid  +ordinary securities cancelled during that  12 month period	Nil	
"A"	244,453,754	

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15	
	[Note: this value cannot be changed]	
	[Note: this value carriot be changed]	
<b>Multiply</b> "A" by 0.15	36,668,063	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	33,000,000 issued on 30 December 2015 3,668,063 issued on 26 January 2016	
<ul> <li>Under an exception in rule 7.2</li> </ul>		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	36,668,063	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-	
"A" x 0.15	36,668,063	
Note: number must be same as shown in Step 2		
Subtract "C"	36,668,063	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	0	
	[Note: this is the remaining placement	

Appendix 3B Page 10 04/03/2013

capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in	244,453,754	
Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	24,445,375	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued	11,331,937 issued on 26 January 2016	
or agreed to be issued in that 12 month period under rule 7.1A	4,000,000 issued on 27 January 2016	
Notes:		
<ul> <li>This applies to equity securities – not just ordinary securities</li> </ul>		
<ul> <li>Include here – if applicable – the</li> </ul>		
securities the subject of the Appendix 3B to which this form is annexed		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with</li> </ul>		
in Part 1), or for which specific security		
<ul> <li>holder approval has been obtained</li> <li>It may be useful to set out issues of</li> </ul>		
securities on different dates as		
"E"	15.331.937	
separate line items	15,331,937	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	24,445,375	
Subtract "E"  Note: number must be same as shown in Step 3	15,331,937	
<i>Total</i> ["A" x 0.10] – "E"	9,113,348  Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.